文献速递胸部肿瘤乳腺癌泌尿男性生殖肿瘤

靶向TGF-β2的反义寡核苷酸抑制肺转移并诱导肿瘤相关巨噬细胞表达CD86

An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.
PubMed 文献 · Ann Oncol · 2017-01-01

本研究在肿瘤细胞培养及原位小鼠模型(乳腺癌、肾癌原发瘤及肺转移)中评估靶向TGF-β2的锁核酸修饰反义寡核苷酸ISTH0047的抗肿瘤效应。ISTH0047显著降低TGF-β2 mRNA和蛋白水平而不改变TGF-β1和TGF-β3,在同基因原位肾癌(RENCA)和乳腺癌(4T1)模型中预防肺转移,并在肺癌细胞系(CRL5807)原位异种移植模型中抑制肺部病灶生长。ISTH0047使肺实质巨噬细胞重新表达肿瘤抑制因子CD86。

要点

  • ISTH0047显著降低TGF-β2 mRNA和蛋白水平,不改变TGF-β1和TGF-β3水平。
  • ISTH0047在同基因原位RENCA和4T1模型中预防肺转移。
  • ISTH0047在CRL5807原位异种移植模型中抑制肺部病灶生长并诱导巨噬细胞表达CD86。

核心结论

  • 数据提示TGF-β2为治疗靶点,ISTH0047作为新型抗癌药通过影响肿瘤微环境(部分通过诱导肿瘤相关巨噬细胞表达CD86)来预防肺转移。

研究设计与样本

  • 研究使用肿瘤细胞培养(裸递送)及体内临床前原位小鼠模型,包括原发肿瘤(乳腺癌和肾癌)和肺转移模型。

主要发现

  • ISTH0047显著降低TGF-β2 mRNA和蛋白水平,而不改变TGF-β1和TGF-β3水平。
  • ISTH0047在同基因原位肾细胞癌(RENCA)和乳腺癌(4T1)肿瘤模型中预防肺转移。
  • 在主要表达TGF-β2的肺癌细胞系(CRL5807)原位异种移植模型中,ISTH0047对肺部微环境有重要影响,抑制肺部病灶生长。
  • ISTH0047治疗使肺实质巨噬细胞重新表达肿瘤抑制因子CD86。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The transforming growth factor (TGF)-β pathway is a well-described inducer of immunosuppression and can act as an oncogenic factor in advanced tumors. Several preclinical and clinical studies show that the TGF-β pathway can be considered a promising molecular target for cancer therapy. The human genome has three TGF-β isoforms and not much is known about the oncogenic response to each of the isoforms. Here, we studied the antitumor response to ISTH0047, a recently developed locked nucleic acid-modified antisense oligonucleotide targeting TGF-β2. MATERIALS AND METHODS: We have studied the anticancer response to ISTH0047 using gymnotic delivery in tumor cell cultures and in in vivo preclinical orthotopic mouse models for primary tumors (breast and kidney tumors) and lung metastasis. RESULTS: We observed that ISTH0047 is able to significantly reduce TGF-β2 mRNA and protein levels without altering the levels of TGF-β1 and TGF-β3. ISTH0047 prevented lung metastasis in syngeneic orthotopic renal cell carcinoma (RENCA) and breast cancer (4T1) tumor models. In addition, using an orthotopic xenograft model of a lung cancer cell line (CRL5807) that mainly expresses TGF-β2, we observed that ISTH0047 had an important effect on the lung microenvironment inhibiting the growth of lung lesions. ISTH0047 treatment re-educated macrophages in the lung parenchyma to express the tumor-suppressive factor, CD86. CONCLUSION: Overall, our data point to TGF-β2 as a therapeutic target and ISTH0047 as a novel anticancer drug to prevent lung metastasis by impacting on the tumor niche, in part, through the induction of CD86 in tumor-associated macrophages.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Huber-Ruano I, Raventós C, Cuartas I, et al. An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Ann Oncol. 2017. PMID: 28911087. doi:10.1093/annonc/mdx314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。